Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Executive Summary
Allergan's second quarter exceeded expectations and full-year guidance was raised slightly, but while the aesthetics business grew, ophthalmology with a 9.4% Restasis decline was a notable outlier.
You may also be interested in...
Allergan, Shire Battle In Dry Eye As Generics Advance
Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.
Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR
The tribe will move to get IPR proceedings dismissed, but the strategy isn't expected to affect ANDA litigation. Allergan's CEO said the company could use a similar approach with other patents and notes that other companies may follow.
Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR
The tribe will move to get IPR proceedings dismissed, but the strategy isn't expected to affect ANDA litigation. Allergan's CEO said the company could use a similar approach with other patents and notes that other companies may follow.